IP Library Granted Patent US 11,998,574
Granted Patent B2
US 11,998,574 · App. 18/235,686 · Granted Jun 4, 2024

Method and system for modulating an individual's skin microbiome

Inventors: Sheri Simmons (Brookline, MA); Tye Jensen (Telluride, CO); Raja Dhir (Venice, CA); Joseph E. Kovarik (Englewood, CO)
Assignee: Seed Health, Inc.
A61K35/74A61K31/58A61K31/715A61K38/1709A61K38/1758A61K2035/11
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,998,574
App. No.
18/235,686
Granted
Jun 4, 2024
Kind
B2
Abstract

Compositions, systems and methods of improving the health of the microbiome of an individual's skin relate to the provision of skin contacting formulations containing beneficial bacteria, postbiotics, metabolites and other microbe components to foster the growth and maintenance of a healthy skin microbiome. One embodiment includes a topical application of Lactobacillus crispatus to ameliorate skin barrier damage and inflammation using unique combinations of probiotics, prebiotics, postbiotics, and other skin-beneficial ingredients, effectively treating inflammatory skin diseases, such as atopic dermatitis, psoriasis and acne, through the production of tryptophan metabolites that act as AHR agonists.

Claims (20)

1. A method of modulating an individual's skin microbiome, comprising: administering to a region of an individual's skin who has a skin condition a therapeutically effective amount of a bacterial formulation comprising at least one bacteria selected from the group consisting of Lactobacillus reuteri, Lactobacillus johnsonii, Janthinobacterium, Lactobacillus crispatus, Cutibacterium acnes , and Nitrosomonas eutropha , said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto a region of the individual's skin, and abiotic augmentations comprising fatty acids, wherein said at least one bacteria comprises a heat-killed bacteria and wherein the bacterial formulation is in an amount effective to treat, inhibit or reduce a skin condition selected from the group consisting of eczema, atopic dermatitis, acne, allergic inflammation, ultra-violet-induced skin damage, and skin hypersensitivity.

2. The method as set forth in claim 1 , wherein the bacterial formulation further comprises one or more of Staphylococcus, Bifidobacterium , and Streptococcus.

3. The method as set forth in claim 1 , further comprising administering to the individual one of a prebiotic, a metabolite, and a postbiotic.

4. The method as set forth in claim 1 , further comprising administering to the individual a cleanser composition comprising at least one of sodium methyl cocoyl taurate, sodium cocoyl glutamate, coco glucoside, caprylyl/capryl glucoside, sodium cocoyl Isethionate, and cetearyl alcohol; a serum composition comprising at least two of the following: indole-3-carbinol, resveratrol, niacinamide, nicotinic acid, nicotinamide mononucleotide, nicotinamide riboside, quercetin, tryptophan, diiodomethane, Boswellia serrata , and indirubin; and at least one barrier-restoring oil comprising at least one of sunflower oil, coconut oil, murumuru oil, sea buckthorn oil, sachi inchi oil, and babbasu oil.

5. The method as set forth in claim 1 , wherein at least some bacteria in the bacterial formulation have been modified by using a using a clustered regularly interspaced short palindromic repeats (CRISPR) CRISPR associated protein (Cas) system or a CRISPR from Prevotella and Francisella 1 (Cpf1) system to reduce the production of a virulence factor.

6. The method as set forth in claim 1 , wherein the at least one bacteria is one of Cutibacterium acnes and Janthinobacterium.

7. The method as set forth in claim 1 , wherein the at least one bacteria in the bacterial formulation produce short-chain fatty acids selected from the group consisting of propionate, acetate, butyrate and valerate.

8. The method as set forth in claim 1 , wherein the at least one bacteria in the bacterial formulation does at least one of: suppress the growth of S. aureus ; reduce the colonization of S. aureus on the individual's skin; and inhibit biofilm formation by S. epidermidis.

9. The method as set forth in claim 1 , further comprising killing or retarding the growth of a pathogenic bacteria within the individual, said pathogenic bacteria selected from the group consisting of Staphylococcus aureus; Pseudomonas aeruginosa; Klebsiella; Streptococcus; Salmonella; Shigella; Mycobacterium tuberculosis; Enterococcus; E coli; Clostridium; Neisseria gonorrhoeae; Acinetobacter baumannii ; and Campylobacter.

10. The method as set forth in claim 1 , wherein said method further comprises enhancing the growth of a beneficial bacteria in the individual selected from the group consisting of C. acnes, Akkermansia, Bacteroides, Bifidobacterium, Fusobacterium, Coprococcus, Lactobacillus, Propionibacterium, Nitrosomonas eutropha, Ruminococcus, Veillonella, Prevotella , and Streptococcus bacteria.

11. The method as set forth in claim 1 , further comprising administering at least two probiotic strains to the individual's skin in a concentration of at least 1×10 8 Arbitrary Fluorescence Units (AFU), said at least two probiotic strains being either live or heat-killed and selected from the group consisting of Cutibacterium, Staphylococcus, Corynebacterium, Micrococcus spp., Actinobacteria, Proteobacteria, and Firmicutes.

12. The method as set forth in claim 1 , further comprising administering to the individual's skin at least one probiotic strain that does not upregulate innate immune response genes selected from the group consisting of CXCL1, CXCL3, CXCL8, CXCL10.

13. The method as set forth in claim 1 , further comprising administering to the individual's skin at least one probiotic strain that does not upregulate innate immune response genes selected from the group consisting of IL10RA, PTGS2, F2RL1, TRIM29, TRAF4, LGALS3, CD55, TRIM8, CASP4, IFNGR1, ADA, NOD1, NOS2, and APP.

14. A method of modulating an individual's skin microbiome, comprising, administering to a region of an individual's skin who has a skin condition a therapeutically effective amount of a bacterial formulation comprising Lactobacillus crispatus , and at least two bacteria selected from the group consisting of Lactobacillus reuteri, Lactobacillus johnsonii, Cutibacterium acnes, Janthinobacterium and Nitrosomonas eutropha , said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto a region of the individual's skin, and abiotic augmentations comprising fatty acids, wherein the at least two bacteria comprise heat-killed bacteria and wherein the skin condition is selected from the group consisting of eczema, atopic dermatitis, acne, allergic inflammation, impetigo, ultra-violet-induced skin damage, and skin hypersensitivity.

15. The method as set forth in claim 14 , wherein the skin condition is selected from the group consisting of atopic dermatitis, and wherein the individual has a skin infection associated with a topical pathogenic microorganism comprising Staphylococcus aureus.

16. The method as set forth in claim 14 further comprising administering to the individual a prebiotic, metabolite, and a postbiotic.

17. The method as set forth in claim 14 , wherein said bacterial formulation further comprises bacteria selected from the group consisting of Faecalibacterium prausnitzii, Bifidobacterium, Lachnospira, Veillonella, Coprococcus, Akkermansia muciniphila and Rothia.

18. A method of modulating an individual's skin microbiome, comprising, topically administering to a region of an individual's skin a therapeutically effective amount of a bacterial formulation comprising heat-killed Lactobacillus crispatus bacteria, and at least one of Lactobacillus reuteri, Lactobacillus johnsonii, Lactobacillus crispatus, Cutibacterium acnes, Bifidobacterium lognum and Nitrosomonas eutropha , said bacterial formulation comprising a lotion, ointment or gel adapted to be rubbed onto a region of the individual's skin, and wherein the bacterial formulation further comprises Janthinobacterium.

19. The method as set forth in claim 18 , further comprising administering to the individual's skin one of arabinogalactan and a UV protectant chemical.

20. The method as set forth in claim 18 , wherein the bacterial formulation is administered to an individual's skin who has a skin condition in an amount sufficient for the bacterial formulation to generate an amount of tryptophan metabolites sufficient to act as aryl hydrocarbon receptor (AHR) agonists to thereby reduce inflammation on the individual's skin, wherein the skin condition is selected from the group consisting of eczema, atopic dermatitis, acne, allergic inflammation, ultra-violet-induced skin damage, and skin hypersensitivity.

Assignments (3)
SECURITY INTEREST Recorded Jul 21, 2026
From: SEED HEALTH, INC.
To: JPMORGAN CHASE BANK, N.A., AS LENDER
Reel/Frame 076028/0339 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 28, 2023
From: DHIR, RAJA
To: SEED HEALTH, INC.
Reel/Frame 065680/0982 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 10, 2023
From: SIMMONS, SHERI; JENSEN, TYE; KOVARIK, JOSEPH E.
To: SEED HEALTH, INC.
Reel/Frame 065173/0432 →
Continuity (63)
Continuation In Part 18130946 · Apr 5, 2023
Continuation In Part 18178847 · Mar 28, 2023
Continuation In Part 18087545 · Dec 22, 2022
Continuation In Part 17854422 · Jun 30, 2022
Continuation In Part 17848759 · Jun 24, 2022
Continuation In Part 17835204 · Jun 8, 2022
Continuation In Part 17567295 · Jan 3, 2022
Continuation In Part 17337600 · Jun 3, 2021
Continuation In Part 17027953 · Sep 22, 2020
Continuation In Part 16917096 · Jun 30, 2020
Continuation In Part 16782364 · Feb 5, 2020
Continuation In Part 16423375 · May 28, 2019
Continuation 16160336 · Oct 15, 2018
Continuation 15403823 · Jan 11, 2017
Continuation In Part 18234132 · Aug 15, 2023
Continuation In Part 18232980 · Aug 11, 2023
Continuation In Part 18232433 · Aug 10, 2023
Continuation In Part 18143399 · May 4, 2023
Continuation 17893384 · Aug 23, 2022
Continuation In Part 17694775 · Mar 15, 2022
Continuation In Part 17023736 · Sep 17, 2020
Continuation In Part 17011175 · Sep 3, 2020
Continuation In Part 16722117 · Dec 20, 2019
Continuation In Part 16229252 · Dec 21, 2018
Continuation In Part 15392173 · Dec 28, 2016
Continuation In Part 18234544 · Aug 16, 2023
Continuation In Part 18103768 · Jan 31, 2023
Continuation In Part 17738771 · May 6, 2022
Continuation In Part 16904056 · Jun 17, 2020
Continuation In Part 15983250 · May 18, 2018
Continuation In Part 15384716 · Dec 20, 2016
Continuation In Part 17836079 · Jun 9, 2022
Continuation In Part 16884772 · May 27, 2020
Continuation In Part 16136950 · Sep 20, 2018
Continuation 15385278 · Dec 20, 2016
Continuation In Part 17543992 · Dec 7, 2021
Continuation In Part 16804361 · Feb 28, 2020
Continuation In Part 16020433 · Jun 27, 2018
Continuation In Part 15342642 · Nov 3, 2016
Continuation In Part 16776861 · Jan 30, 2020
Continuation 16142171 · Sep 26, 2018
Continuation In Part 15395419 · Dec 30, 2016
Continuation In Part 16426346 · May 30, 2019
Continuation 15639767 · Jun 30, 2017
Continuation In Part 15437976 · Feb 21, 2017
Continuation In Part 15228454 · Aug 4, 2016
Continuation In Part 14954074 · Nov 30, 2015
Continuation In Part 15270034 · Sep 20, 2016
Continuation In Part 14954074 · Nov 30, 2015
Continuation In Part 14574517 · Dec 18, 2014
Continuation In Part 16037053 · Jul 17, 2018
Continuation In Part 14752192 · Jun 26, 2015
Provisional Application 62260906 · Nov 30, 2015
Provisional Application 62296186 · Feb 17, 2016
Provisional Application 62275341 · Jan 6, 2016
Provisional Application 62387405 · Dec 24, 2015
Provisional Application 62387404 · Dec 24, 2015
Provisional Application 62274550 · Jan 4, 2016
Provisional Application 62072476 · Oct 30, 2014
Provisional Application 62053926 · Sep 23, 2014
Provisional Application 62014855 · Jun 20, 2014
Provisional Application 61919297 · Dec 20, 2013
Related Publication 20240024378A1 · Jan 25, 2024
Cited By (7)
US 12,257,272 US 12,279,989 US 12,318,411 US 12,318,414 US 12,329,783 US 12,357,662 US 12,533,312